Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 61, No 3 (2010)
Case report
Submitted: 2013-02-15
Published online: 2010-07-02
View PDF Download PDF file
Get Citation

The role of combined low-dose dexamethasone suppression test and desmopressin stimulation test in the diagnosis of persistent Cushing’s disease. Case report

Przemysław Witek, Wojciech Zgliczyński, Grzegorz Zieliński, Wojciech Jeske
Endokrynol Pol 2010;61(3):312-317.

open access

Vol 61, No 3 (2010)
Case report
Submitted: 2013-02-15
Published online: 2010-07-02

Abstract

Cushing’s disease is related to a significant increase in mortality due to chronic hypercortisolaemia complications. It is known that 50% of non-treated subjects die within 5 years. Transsphenoidal selective adenomectomy is the treatment of choice. The incidence of relapses, even following a successful surgical procedure, is high and reaches 20–25% during the 5-year follow-up period.
The authors discuss the case of a patient, currently aged 60, after repeat pituitary surgery, with progressive cardiovascular complications, in whom persistent Cushing’s disease was diagnosed. The diagnosis was determined despite normal plasma ACTH, serum cortisol levels, and 17-OHCS concentrations in daily urine. There was also a lack of obvious pituitary adenoma features in the magnetic resonance imaging (MRI). Persistent Cushing’s disease was diagnosed based on the combined dexamethasone desmopressin test.
The presented case points to the role of provocative testing, including the desmopressin test following 1 mg of dexamethasone, for diagnostically difficult cases of Cushing’s disease.
(Pol J Endocrinol 2010; 61 (3): 312-317)

Abstract

Cushing’s disease is related to a significant increase in mortality due to chronic hypercortisolaemia complications. It is known that 50% of non-treated subjects die within 5 years. Transsphenoidal selective adenomectomy is the treatment of choice. The incidence of relapses, even following a successful surgical procedure, is high and reaches 20–25% during the 5-year follow-up period.
The authors discuss the case of a patient, currently aged 60, after repeat pituitary surgery, with progressive cardiovascular complications, in whom persistent Cushing’s disease was diagnosed. The diagnosis was determined despite normal plasma ACTH, serum cortisol levels, and 17-OHCS concentrations in daily urine. There was also a lack of obvious pituitary adenoma features in the magnetic resonance imaging (MRI). Persistent Cushing’s disease was diagnosed based on the combined dexamethasone desmopressin test.
The presented case points to the role of provocative testing, including the desmopressin test following 1 mg of dexamethasone, for diagnostically difficult cases of Cushing’s disease.
(Pol J Endocrinol 2010; 61 (3): 312-317)

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Cushing’s disease; desmopressin test; hypercortisolaemia

About this article
Title

The role of combined low-dose dexamethasone suppression test and desmopressin stimulation test in the diagnosis of persistent Cushing’s disease. Case report

Journal

Endokrynologia Polska

Issue

Vol 61, No 3 (2010)

Article type

Case report

Pages

312-317

Published online

2010-07-02

Page views

548

Article views/downloads

1965

Bibliographic record

Endokrynol Pol 2010;61(3):312-317.

Keywords

Cushing’s disease
desmopressin test
hypercortisolaemia

Authors

Przemysław Witek
Wojciech Zgliczyński
Grzegorz Zieliński
Wojciech Jeske

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl